News
CKPT
--
0.00%
--
Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
Insider Monkey · 16h ago
Checkpoint Therapeutics Q3 EPS $(0.09) Up From $(0.15) YoY
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.09) per share. This is a 40 percent increase over losses of $(0.15) per share from the same period last year.
Benzinga · 11/04 22:14
Checkpoint Therapeutics EPS misses by $0.01, misses on revenue
Checkpoint Therapeutics (CKPT): Q3 GAAP EPS of -$0.09 misses by $0.01.Revenue of $0.03M (-89.3% Y/Y) misses by $0.16M.Cash and cash equivalents of $42M.Press Release
Seekingalpha · 11/04 21:42
Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Checkpoint Therapeutics (CKPT) and Samsung Biologics expand their long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.Building upon an existing agreement entered into in 2017, Samsung Bio will provide additional commercial-scale drug
Seekingalpha · 11/02 12:35
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
Samsung Biologics Co., Ltd. ("Samsung Biologics") (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), today announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Under the new agreement, Samsung Biologics will commence manufacturing in 2021 in Plant 1.
PR Newswire · 11/02 12:00
Checkpoint Therapeutics announces $20M bought deal offering
Checkpoint Therapeutics (CKPT) enters into an underwriting agreement with H.C. Wainwright & Co to purchase 7,142,857 shares at a price of $2.80 per share, less underwriting discounts and commissions. Offering expected
Seekingalpha · 09/17 21:37
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter
GlobeNewswire · 09/17 21:27
Sorrento Therapeutics, Phio Pharmaceuticals leads healthcare gainers, Strongbridge Biopharma, Nano-X Imaging among major losers
Gainers: Sorrento Therapeutics (SRNE) +24%, Entera Bio (ENTX) +23%,  Vaccinex (VCNX) +17%, Vaxart (VXRT) +15%, Phio Pharmaceuticals (PHIO) +14%Losers: Strongbridge Biopharma (SBBP) -19%, Nano-X Imaging (NNOX) -16%, Checkpoint Therapeutics (CKPT) -14%, NuCana (NCNA) -11%, Inovio Pharmaceuticals (INO) -11%.
Seekingalpha · 09/17 15:07
Checkpoint Therapeutics' cosibelimab shows encouraging action in skin cancer study
Checkpoint Therapeutics (CKPT) perks 6% premarket after announcing updated interim results from the ongoing Phase 1 clinical trial of its anti-PD-L1 antibody, Cosibelimab (formerly referred to as CK-301), in patients with advanced cancers,
Seekingalpha · 09/17 11:05
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort Interim results presented at ESMO Virtual Congress 2020 On track to report full top-line results in
Benzinga · 09/17 10:33
Checkpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress
With interim results from a pivotal clinical trial of its lead PD-L1 checkpoint inhibitor incoming, biotech firm Checkpoint Therapeutics (NASDAQ: CKPT) is poised to deliver an important update on the drug's efficacy and tolerability in its initial indication as a potential treatment for cutaneous
Benzinga · 09/14 11:19
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020
GlobeNewswire · 08/17 13:00
Checkpoint Therapeutics EPS in-line, misses on revenue
Checkpoint Therapeutics (NASDAQ:CKPT): Q2 GAAP EPS of -$0.09 in-line. Revenue of $0.04M (-96.2% Y/Y) misses by $0.35M. Press Release
seekingalpha · 08/06 01:50
Checkpoint Therapeutics To Present Cosibelimab Interim Results From Registration-Enabling Trial At ESMO Virtual Congress 2020
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma   Over 50% of enrollment target achieved; full enrollment expected around
Benzinga · 07/27 11:34
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
* Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma * Over 50% of enrollment target achieved; full enrollment expected around year-end * Potential for cosibelimab to be a best-in-
GlobeNewswire · 07/27 11:30
RAD, INO among premarket gainers
Seeking Alpha - Article · 06/25 12:14
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 05/22 13:30
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
The following article is sponsored by the clinical communications unit of investor relations firm Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended
Benzinga · 05/20 12:33
Checkpoint Therapeutics Q1 EPS $(0.060) Up From $(0.180) YoY
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.060) per share. This is a 66.67 percent increase over losses of $(0.180) per share from the same period last year.
Benzinga · 05/06 21:08
Webull provides a variety of real-time CKPT stock news. You can receive the latest news about Checkpoint Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CKPT
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
More